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Molecular alterations of the signal transduction pathway compo-
nents are frequently associated with the transformation process
and, therefore, they provide specific targets for novel antitumour
approaches. In this regard, a widely studied pathway is the Ras-
dependent mitogen activated protein kinases (MAPKs) cascade
that transduces signals from the membrane growth factor-receptor
tyrosine kinases to the nucleus where it triggers cell proliferation
(see also Figure 6). The binding of epidermal growth factor (EGF)
to its receptor induces the autophosphorylation of the receptor’s
tyrosine residues (Ullrich and Schlessinger, 1990) that recruit
multiple cellular components such as the Grb2 adapter protein and
the GTP/GDP exchange factor SOS (Denhardt, 1996). Such events
result in the formation of a specific protein complex leading to the
activation of p21ras GTPase (Denhardt, 1996). The GTP-bound
form of p21ras induces the translocation to the cell membrane and
the activation of the serine-threonine protein kinase Raf-1
(Marshall, 1996), which in turn activates a family of dual
specificity kinases known as mitogen-activated/extracellular-
signal regulated kinase kinase or MEK. MEK is the component of
the cascade of phosphorylation events downstream of growth
factor receptors, which finally stimulates the extracellular-signal-
regulated kinases (ERKs) (Crews and Erikson, 1993). These
enzymes, ERK-1 and ERK-2, belong to a subgroup of MAPKs, a
serine/threonine kinases family, which require phosphorylation on
both a threonine and a tyrosine residue for their activation and
which transmit the mitogenic signal into the nucleus by regulating
gene expression through the phosphorylation of a variety of tran-
scription factors (Marshall, 1996). Several attempts have been
made to inhibit this pathway whose components are individually
capable of inducing malignant transformation when aberrantly
controlled (Huang, 1997).
The interference on the Ras-dependent ERKs cascade by agents
targeted on different signalling pathways is considered an addi-
tional therapeutical approach (Wu et al, 1993). In fact, several
studies have reported that cyclic AMP (cAMP) elevating agents,
which activate cAMP-dependent protein kinase (PKA), also
induce phosphorylation of Raf-1, preventing its activation by
p21ras and finally lead to the inhibition of the ERKs cascade (Cook
and McCormick, 1993; Wu et al, 1993; Hordijk et al, 1994).
However, it has also been reported that PKA-mediated inhibition
of cell growth may occur through modulation of intracellular
targets distinct from the ERKs cascade (McKenzie and
Pouysségur, 1996). On the other hand, PKA is able to stimulate the
ERKs cascade in PC12 and in epithelial cells (Frodin et al, 1994;
Vossler et al, 1997), and it is also involved in non-ERKs-
stimulated mitogenic pathways (Withers et al, 1995). Taken
together, such findings suggest that cAMP and PKA may produce
different and apparently conflicting effects on mitogen-activated
signal transduction pathways.
8-Chloro-cAMP (8-Cl-cAMP), a synthetic cAMP analogue, is a
powerful inhibitor of tumour cell growth both in vivo and in vitro
(Tagliaferri et al, 1988; Cho-Chung 1989; Bosanquet et al, 1997;
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Fassina et al, 1997; Tortora et al, 1997b; Langdon et al, 1998).
Moreover, phase I clinical studies on 8-Cl-cAMP have been
recently completed in cancer patients (Tortora et al, 1995;
Saunders et al, 1997). The molecular mechanism of the growth
inhibitory action of 8-Cl-cAMP has been proposed to result from
the selective modulation of the two isoenzymes of PKA, type I
(PKA-I) and type II (PKA-II) (Cho-Chung et al, 1995). These
enzymes appear to differently modulate cell growth and differenti-
ation. PKA-I is overexpressed in tumour cells and is increased in
normal cells upon exposure to mitogenic stimuli (Miller et al,
1993; Tortora et al, 1993; Cho-Chung et al, 1995), whereas
PKA-II expression is typical of terminally differentiated tissues
and growth-arrested cells (Schwartz and Rubin, 1985; Budillon et
al, 1995; Cho-Chung et al, 1995). 8-Cl-cAMP treatment of tumour
cells reduces PKA-I activity and concomitantly increases PKA-II
activity (Rohlff et al, 1993; Budillon et al, 1995; Cho-Chung et al,
1995; Scala et al, 1995). Therefore, the catalytic activity of PKA
may be affected by 8-Cl-cAMP through regulation of the expres-
sion of the two isoenzymes rather than by direct activation, as
previously demonstrated (Scala et al, 1995). The wide range of
cancer cells whose growth is inhibited by 8-Cl-cAMP suggests a
common mechanism of action that is likely to involve perturbation
of an ubiquitous signal transduction pathway that initiates prolifer-
ation in a broad number of different cell systems, such as the
mitogen-activated Ras-dependent ERKs cascade. Moreover, some
reports show that 8-Cl-cAMP may interfere with growth factor
autocrine pathways and growth factor-induced transformation
(Ciardiello et al, 1996; Bianco et al, 1997). Therefore, 8-Cl-cAMP
represents a suitable tool for studying pharmacological inter-
ference on disregulated mitogenic pathways in tumour cells.
In the present study we have investigated the effects exerted by
8-Cl-cAMP on the EGF-mediated signal transduction pathway.
We have selected as experimental model the KB epidermoid carci-
noma cell line that is responsive to the mitogenic stimulus induced
by EGF (Aboud-Pirak et al, 1988; Caraglia et al, 1995) and is
growth inhibited by 8-Cl-cAMP treatment. We have found that the
growth-promoting activity of EGF on KB cells was completely
abolished by 8-Cl-cAMP. Furthermore, we have shown that this
effect was associated to the specific inhibition of ERKs (ERK-1
and ERK-2) activity induced by 8-Cl-cAMP, while the function of
the upstream components of the EGF-induced mitogenic pathway
was preserved.
MATERIALS AND METHODS
Materials
8-Cl-cAMP (8-Chloro-cyclic adenosine 3¢,5¢-monophosphate,
sodium salt) was provided by KP Flora, National Cancer Institute
(NCI), National Institutes of Health (Bethesda, MD, USA) 
8-Bromo-cAMP and 8-Chloro-adenosine (8-Cl-adenosine) were
purchased from BioLog Life Science Institute (Bremen,
Germany). [methyl-3H]thymidine (25 Ci mmol–1), [125I]EGF (30
mCi mg–1) and [g32P]ATP (3000 Ci mmol–1) were from Amersham
(Buckinghamshire, UK). Protease inhibitors, receptor grade EGF,
PMA, and forskolin were from Sigma Chemical Co. (St Louis,
MO, USA). The anti-phosphotyrosine 4G10 and anti-PLC-g1
mouse monoclonal antibodies (mAbs) were purchased from
Upstate Biotechnology Inc. (Lake Placid, NJ, USA). The antisera
anti-Raf-1, anti-ERK-1, anti-ERK-2, anti-MEK-1, anti-EGF-R
and the anti-EGF-R 528 mAb were purchased from Santa Cruz
Biotechnology Inc. (Santa Cruz, CA, USA). Anti-CDK4 poly-
clonal antibody is from Pharmigen (Missisauga, Canada). Rabbit
and mouse Ig, horseradish peroxidase-linked (HRP) antibodies
and enhanced chemiluminescence (ECL) immunodetection
reagents were from Amersham (Buckinghamshire, UK). Protein-
A-Sepharose CL-4B is from Pharmacia (Uppsala, Sweden). All
media, serum, antibiotics and glutamine are from Gibco (Grand
Island, NY, USA).
Cell culture and cell proliferation assays
The human epidermoid carcinoma KB cell line, obtained from
American Type Tissue Culture Collection (Rockville, MD, USA),
was grown in Dulbecco’s modified Eagle’s medium (DMEM)
supplemented with 10% heat inactivated fetal bovine serum, peni-
cillin (50 units ml–1), streptomycin (500 mg ml–1), 20 mM HEPES,
pH 7.4, and 4 mM glutamine, in a humidified atmosphere of 95%
air and 5% carbon dioxide at 37°C. KB cells throughout all the
experiments have been maintained in serum-containing medium
and no EGF deprivation has been performed to enhance EGF
effects on cell growth or protein phosphorylation. For cell growth
assays 1.5 ´ 105 cells were seeded in triplicate in 6-multiwell
(Corning Glass, Corning, NY, USA), 8-Cl-cAMP and/or EGF was
added at indicated concentrations after 3 h from seeding. At
selected times cell growth assessment was performed by haemocy-
tometric cell count and Trypan blue viability assay, following
gentle trypsinization. The statistical significance of the difference
in cell growth with and without the addition of 8-Cl-cAMP and
EGF was evaluated by analysis of variance. Statistical evaluation
was performed with the BMDP statistical software package.
Determination of DNA synthesis
A total of 2 ´ 104 cells well–1 were incubated in 24-multiwell for
48 h with or without 8-Cl-cAMP, in the presence or absence of the
indicated concentrations of EGF for the last 18 h, and then were
pulsed with 0.5 mCi [methyl-3H]thymidine (25 Ci mmol–1) for
5 h. Incubations were stopped by washing cells four times with
phosphate-buffered saline (PBS) followed by fixation with 5%
ice-cold trichloroacetic acid (TCA) at 4°C for 30 min. Cells were
then washed twice with ethanol and dissolved in 20 mM sodium
hydroxide and 1% sodium dodecyl sulphate (SDS) and finally
transferred to scintillation solution (Packard, Meriden, CT, USA)
for radioactivity determination. The statistical significance of the
difference in thymidine incorporation with and without 8-Cl-
cAMP and EGF was evaluated by analysis of variance. Statistical
evaluation was performed with the BMDP statistical software
package.
Tyrosine phosphorylation and immunoblotting
To characterize the pattern of tyrosine phosphorylation, KB cells
were grown for 48 h with or without 10 mM 8-Cl-cAMP and were
exposed for the indicated times to 10 nM EGF at 37°C. After
harvesting by scraping and centrifugation, cells were washed once
in PBS and lysed in buffer A (50 mM HEPES, 150 mM sodium
chloride (NaCl), 1.5 mM magnesium chloride (MgCl2), 5 mM
EGTA, 1% glycerol, 1% Triton X-100, 20 mM sodium pyro-
phosphate, 10 mM sodium orthovanadate, 25 mM NaF, 1 mM
phenylmethyl sulphonyl fluoride (PMSF), 0.4 mg ml–1 aprotinin,
10 mg ml–1 leupeptin). Equal volumes of sample buffer (62.5 mM1136 A Budillon et al
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Tris–HCl pH 6.8, 20% glycerol, 2% SDS, 5% b-mercaptoethanol,
0.5% (w/v) bromophenol blue) were added to the samples and
heated at 95°C for 3 min. Forty micrograms of total protein from
each sample were separated by 10% SDS polyacrylamide gel
electrophoresis (PAGE) and then transferred to nitrocellulose
paper. The membranes were immunoblotted with anti-phosphoty-
rosine 4G10 mAb and probed with HRP-linked sheep anti-mouse
IgG. Detection by ECL was performed as recommended in the
manufacturer’s instructions. For EGF-R autophosphorylation and
PLC-g1 tyrosine-phosphorylation, 0.5 mg of cell lysates were
immunoprecipitated with anti-EGF-R 528 and anti-PLC-g1 mAbs
respectively and immune complexes were isolated by protein A
and protein G sepharose respectively. Immunoprecipitated
proteins were eluted by boiling the immune complexes in 25 ml
sample buffer and resolved by 8% SDS-PAGE. Immunoblots with
anti-phosphotyrosine mAb were prepared and probed as pre-
viously described. Primary and secondary antibodies were then
extracted from membranes using buffer B (62.5 mM Tris–HCl
pH 6.7, 100 mM b-mercaptoethanol and 2% SDS) and reprobed
with anti-EGF-R polyclonal Ab or anti-PLCg1 mAb, HRP anti-
rabbit or anti-mouse IgG respectively and ECL. CDK4, ERK-1,
ERK-2 and MEK-1 immunoblots were performed as described
above, on total cell lysates subjected to 10% SDS-PAGE. Where
indicated, 10% acrylamide gels containing 2% SDS were used, to
improve resolution of closely migrating forms of ERK or MEK.
Protein kinase assays
KB cells were cultured and treated as described above. MAPK
activity assay was performed on immune-complexes as previously
described (Kharbanda et al, 1994). In brief, cells were washed
twice with ice-cold PBS, scraped and 1ysed for 1 h at 4°C in the
buffer C (10 mM Tris, 150 mM NaCl, 2 mM EGTA, 2 mM dithio-
threitol (DTT), 1 mM sodium orthovanadate, 1 mM PMSF, 10 mg
ml–1 aprotinin, 10 mg ml–1 leupeptin and 1% glycerol) clarified by
centrifugation and equivalent aliquots were incubated with anti-
ERK-1 or anti-ERK-2 antisera and protein A-Sepharose for
16 h at 4°C. The immunoprecipitate was washed twice with buffer
C and twice with buffer D: 20 mM HEPES pH 7.5, 10 mM magne-
sium acetate, 100 mM ATP, 1 mM sodium orthovanadate, 1 mM
PMSF, 10 m ml–1 aprotinin, 10 mg ml–1 leupeptin. The immuno-
complex was then suspended in 30 ml buffer A containing 10 mCi
of [g32P]ATP and 10 mg of myelin basic protein (MBP, Sigma) and
the reaction allowed to proceed for 30 min at 30°C. An equal
volume of 2 ´ sample buffer was then added and the samples were
incubated at 90°C for 5 min. The proteins were separated by
SDS-12.5% PAGE that was stained with Coomassie blue, dried
and then subjected to autoradiography. Alternatively the reaction
mixtures were stopped with the addition of 2.94% (w/v)
orthophosphoric acid and red carmosin solution, centrifuged for 15
s and then spotted onto phosphocellulose filters (Whatman P81).
Filters were washed 3 times in 1% acetic acid, air-dried and then
counted by liquid scintillation using Omnifluor/toluene (DuPont-
New England Nuclear, Boston, MA, USA). The statistical signifi-
cance of the difference in ERK-1 or ERK-2 activity with and
without 8-Cl-cAMP was evaluated by analysis of variance.
Statistical evaluation was performed with the BMDP statistical
software package.
Assay for Raf-1 kinase activity was performed by immunocom-
plex kinase assay as already described for MAPK using anti-Raf-1
antiserum. H1 histone (10 mg) (Upstate Biotechnology Inc.) was
used as substrate, as previously described (Kharbanda et al, 1994)
in 30 ml of buffer A containing 10 mCi of [g32P]ATP, the reaction
was allowed to proceed for 30 min at 30°C and the proteins were
separated by SDS-12.5% PAGE. To measure MEK-1 kinase
activity cell lysates were prepared as described before by immuno-
complex kinase assay using anti-MEK-1 antiserum. A substrate
containing Thr-183 and Tyr-185 within the regulatory sequence
common to ERK-1 and ERK-2 (Santa Cruz Biotechnology Inc,
Santa Cruz, CA, USA) was used and the proteins were separated
by SDS-15% PAGE.
RESULTS
Effects of 8-Cl-cAMP on EGF-induced cell growth
In order to assess if 8-Cl-cAMP interferes with EGF mitogenic
signalling in KB cells, we examined the effect of 8-Cl-cAMP on
the EGF-induced tumour cell proliferation. A cell proliferation
assay, using two doses of EGF in the presence or absence of 10 mM
8-Cl-cAMP for different times, is presented in Figure 1. EGF
alone, at concentrations between 1 nM and 10 nM, which is the
concentration range near the Kd values of the low affinity recep-
tors, brought about the maximal stimulation of KB cell growth
after 96 h. However, the proliferative response to EGF was
completely abolished in the presence of 8-Cl-cAMP. 8-Cl-cAMP
alone induced up to 70% growth inhibition after 96 h (Figure 1),
which occurred without citotoxicity as demonstrated by Trypan
blue assay (data not shown). Since KB cells can be growth-stimu-
lated by EGF even in the presence of serum (Aboud-Pirak et al,
1988) and in order to mimic more physiological conditions, cells
were allowed to grow in 10% serum throughout this and all further
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Figure 1 Effects of 8-Cl-cAMP on cell growth stimulation induced by EGF
in KB cells. Cells were seeded at 1.5 ´ 105 cells well–1 in 6-well culture plates
and exposed for different time points to two concentrations of EGF (1 and
10 nM) in the absence or presence of 10 mM 8-Cl-cAMP. Cell growth
assessment was performed by haemocytometric cell counts following gentle
trypsinization. The data show means of three separate experiments of
duplicate determinations. The difference between the values of 8-Cl-cAMP or
EGF-treated cells versus untreated cells were statistically significant
(P < 0.005). Cell viability, assessed by Trypan blue, was consistently above
80%. Bars, s.d.MAP kinase modulation by cAMP analogue 1137
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experiments. Moreover, when cells were starved for 24 h and
treated in serum-free medium, while the kinetic of EGF stimula-
tion appeared different, probably because the interference of
autocrine growth factor stimulation activated by the starvation
stress, similar results were obtained for 8-Cl-cAMP effect (data
not shown).
Effect of 8-Cl-cAMP on DNA synthesis and ERKs
activation
DNA synthesis and ERKs activation are early events in EGF
growth-promoting activity (Marshall, 1996). DNA synthesis in
response to EGF was measured by [3H]thymidine incorporation
assay. Maximal stimulation of [3H]thymidine incorporation was
obtained after exposure to 10 nM EGF for 18 h. When KB cells
were incubated with 8-Cl-cAMP (10 mM) for 48 h in the presence
of EGF for the last 18 h, the EGF-induced DNA synthesis was
completely blocked (Figure 2A).
ERK-1 and ERK-2 activities were measured by an immuno-
complex-kinase assay using the myelin basic protein (MBP) as
substrate. As shown in Figure 2B and 2C, maximal activation of
ERK-1 and ERK-2 was achieved 5 min after the addition of EGF
while a specific inhibition of basal and EGF-induced activity was
demonstrated in 8-Cl-cAMP-treated cells. ERK-1 stimulation by
EGF was completely abrogated by 8-Cl-cAMP while ERK-2
activation was significantly reduced (Figure 2 B, C).
In order to study whether 8-Cl-cAMP inhibited specifically
EGF-induced ERK-1 and ERK-2 activity or could be replicated in
cells stimulated also by other ERK activators, MAPK activity was
evaluated after exposure of both control and 8-Cl-cAMP-treated
cells to phorbol 12-myristate 13-acetate (PMA). As shown in
Figure 2D, 8-Cl-cAMP completely inhibited the stimulation of
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Figure 2 Effects of 8-Cl-cAMP on DNA synthesis and MAPK activation induced by EGF. (A) KB cells growing in exponential phase in the presence or absence
of 10 mM 8-Cl-cAMP for 48 h were stimulated with different concentrations of EGF for the last 18 h and [3H]thymidine was added for the last 6 h. Incorporation of
thymidine was detected on harvested cells by a liquid scintillation counter. Values are the means of three separate experiments of triplicate determinations;
Bars, s.d.; *P < 0.005 as compared to untreated cells (CTR). (B) ERK-1 activity, (C) ERK-2 activity. Cells have been cultured for 48 h in the absence (•) or
presence of 10 mM 8-Cl-cAMP (n) and exposed for the indicated times to 10 nM EGF. ERK-1 or ERK-2 activity is shown as per cent of the maximum activity (the
value at 5 min of EGF treatment) and was determined by immunocomplex kinase assay as described in Materials and Methods using MBP as substrate. Each
data point is the average of three separate experiments of triplicate determinations; standard errors never exceeded 10%; for each time point the difference
between 8-Cl-cAMP-treated and untreated cells was statistically significant (P < 0.005, except for 30 min time point in B). (D) PMA- and EGF-induced ERK-1
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ERK-1 activity in response to both EGF and PMA. Moreover, it
was previously shown that 8-Cl-cAMP can be hydrolysed to 8-Cl-
adenosine by the serum-phosphodiesterases and 5¢-nucleotidase
and has been hypothesized that the latter molecule can be indeed
responsible for the effects of 8-Cl-cAMP (Lange-Carter et al,
1993; Langeveld et al, 1997). However, in our experimental condi-
tions, the inhibition of ERK-1 activity induced by 8-Cl-cAMP was
not due to the metabolite because 8-Cl-adenosine, while inducing
over 50% cell growth inhibition (data not shown), did not modify
EGF-stimulated or PMA-stimulated ERK-1 activity (Figure 2D).
A time-course evaluation of the effects exerted by 8-Cl-cAMP
on EGF-induced ERKs activation demonstrated that inhibition
occurred only after 48 h treatment, whereas the treatment for 24 h,
4 h or 30 min had no effect (Figure 3) even using concentrations as
high as 1 mM of 8-Cl-cAMP (data not shown). Conversely, treat-
ment for 30 min with the cAMP elevating agent forskolin or with
the cAMP analogue 8-Br-cAMP, both PKA activators, blocked
ERKs activation (Figure 3), confirming previous results (Cook and
McCormick, 1993; Wu et al, 1993; Hordijk et al, 1994). Anti-
ERK-1 immunoblot was used for normalization of the immuno-
complex kinase assay and the ERK-1 relative activity is shown in
Figure 3. As a consequence of these results we carried out all
further experiments exposing the cells to 8-Cl-cAMP for 48 h.
Effects of 8-Cl-cAMP on EGF signalling
Since 8-Cl-cAMP antagonized the growth-promoting activity of
EGF and inhibited the EGF-induced ERKs activation, we investi-
gated the effects of this compound on the components of the EGF-
induced signalling located upstream ERKs. We investigated
whether the inhibition of EGF-induced ERKs activation and DNA
synthesis, exerted by 8-Cl-cAMP, could be dependent on the
decreased expression or function of EGF-R. We tested the effect of
8-Cl-cAMP on EGF-R activation by studying the EGF-induced
receptor autophosphorylation (Figure 4A). Treatment of the cells
with 10 nM EGF for 10 min induced a 20-fold increase of EGF-R
tyrosine phosphorylation as determined by laser scanner densito-
metry of Western blot data. Surprisingly, basal EGF-R tyrosine
phosphorylation in 8-Cl-cAMP-treated cells was threefold
increased and, upon EGF treatment, it further increased up to
25-fold. This effect was paralleled by a threefold increase of
EGF-R expression (Figure 4B). We also examined tyrosine phos-
phorylation of phospholipase C-g1 (PLCg1) which is catalysed by
the activated EGF-R-tyrosine kinase (Denhardt, 1996). As shown
in Figure 4C, EGF induced PLCg1 tyrosine phosphorylation in
control as well as in 8-Cl-cAMP-treated cells while immunoblot
with anti-PLCg1 antiserum revealed equal amount of PLCg1
protein in all immunoprecipitates (Figure 4D). Finally, we
measured the effect of 8-Cl-cAMP on EGF-induced tyrosine
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Figure 3 Time course of 8-Cl-cAMP effect on EGF-induced ERK-1
activation. KB cells growing in exponential phase were untreated or treated
with 10 mM 8-Cl-cAMP for the indicated times, with 25 mM forskolin or 0.5 mM
8-Br-cAMP for 15 min, and then stimulated for 5 min with 10 nM EGF. ERK-1
was immunoprecipitated and analysed for kinase activity using
immunocomplex kinase assay and, for ERK-1 protein expression, by
Western blotting, as described in Materials and Methods. The lower panel
shows the ERK-1 relative activity calculated by laser scanner densitometry
and normalized for protein levels. The experiment shown is one of three
experiments that gave similar results
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Figure 4 EGF-induced tyrosine phosphorylation of EGF-R, PLCg1 and
whole cell proteins in 8-Cl-cAMP-treated cells. KB cells growing in
exponential phase in the presence or absence of 10 mM 8-Cl-cAMP for 48 h,
were stimulated with 10 mM EGF for 5 min. Immunoprecipitated complex
performed with the indicated antibodies (IP), were electrophoresed on
SDS-PAGE, as described in Materials and Methods, transferred to
nitrocellulose membranes, immunostained with the indicated antibodies (IB)
and detected by ECL. Each experiment shown is representative of at least
three experiments that gave similar resultsMAP kinase modulation by cAMP analogue 1139
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phosphorylation of whole cell lysate proteins. As shown in Figure
4E, treatment with 8-Cl-cAMP alone increased basal tyrosine
phosphorylation while the same extent of EGF-stimulated tyrosine
phosphorylation was demonstrated in control as well as in 8-Cl-
cAMP-treated cells. Cyclin-dependent kinase 4 (CDK4) protein
expression was evaluated by Western blotting as control for equal
protein loading (Figure 4F).
It was recently reported that the PKA-induced phosphorylation
of Raf-1 kinase prevented the interaction with membrane-bound
activated p21ras inducing the inhibition of the ERKs cascade (Wu
et al, 1993). In order to study the effect of 8-Cl-cAMP on Raf-1
kinase activity we performed an immunocomplex kinase assay
using H1 histone as Raf-1 substrate (Kharbanda et al, 1994). As
shown in Figure 5A, treatment of KB cells for 48 h with 10 mM
8-Cl-cAMP did not affect EGF-induced Raf-1 kinase activity. The
latter finding indicated again that the mechanism of 8-Cl-cAMP-
induced inhibition of ERKs is different from the previously
reported PKA-mediated mechanism of action (Wu et al, 1993).
In the EGF-induced pathway Raf-1 kinase activates
MAPK/Extracellular signal-regulated kinase also known as MEK,
which in turn induces activation of ERKs (Denhardt, 1996).
Therefore, to further characterize the mechanism of ERKs inhibi-
tion by 8-Cl-cAMP, we evaluated EGF-induced MEK-1 activity in
control as well as in 8-Cl-cAMP-treated cells. As shown in Figure
5B, treatment of KB cells for 48 h with 10 mM 8-Cl-cAMP did not
affect EGF-induced phosphorylation of MEK-1 as detected on
anti-MEK-1 immunoblot where the phosphorylated form of MEK
showed a slower electrophoretic mobility on a 10% acrylamide gel
containing 2% SDS (see ‘Material and Methods’). However, after
stripping and reprobing the same blot with anti-ERK-1 antiserum
the EGF-stimulated active form of ERK-1, which showed reduced
mobility, disappeared in 8-Cl-cAMP-treated cells (Figure 5B,
lower panel). MEK-1 activity was also evaluated by an immuno-
complex kinase assay using a specific peptide substrate containing
Thr-183 and Tyr-185 within the regulatory sequence common to
ERK-1 and ERK-2. As shown in Figure 5C, we could not detect
any change in EGF-induced MEK-1 kinase activity or MEK-1
protein expression upon 8-Cl-cAMP treatment.
DISCUSSION
In this work we have shown that 8-Cl-cAMP antagonizes the
EGF-induced cell proliferation and DNA synthesis in KB epider-
moid cancer cells by interfering with ERKs activation, which is a
crucial event in the signalling cascade of the EGF-mediated mito-
genic pathway (Denhardt, 1996).
We have challenged the hypothesis that the impairment of KB
cell response to EGF could be due to a down-regulation of the
EGF-R expression or function. However, EGF-R expression was
not reduced by 8-Cl-cAMP that, conversely, induced an increase
in the cellular content of EGF-R. Upregulation of EGF-R expres-
sion by 8-Cl-cAMP was paralleled by an increase in tyrosine
phosphorylation of EGF-R and of total cell protein in treated cells.
Therefore, 8-Cl-cAMP enhanced the activation of the early
components in the EGF-induced signalling cascade while it
neutralized the EGF-stimulated cell growth. Moreover, we have
recently demonstrated that 8-Cl-cAMP induces an increase in
EGF-R surface expression, which is dependent on an increase in
EGF-R synthesis (Caraglia et al, 1999). We think that these appar-
ently contradictory results could be, at least in part, explained by
several previous findings from our group and others. In fact, we
have reported that an upregulation of EGF-R is associated to the
growth inhibition of human tumour cells induced by interferon-a
(IFN-a) or by anticancer drugs, such as 1-b-D-arabinofuranosylcy-
tosine (ARA-C), used at cytostatic concentrations (Budillon
et al, 1991; Caraglia et al, 1993). EGF-R up-regulation has also
been reported after tumour cell treatment with low doses of
adriamycin or retinoic acid (Jetten, 1980; Zuckier and Tritton,
1983). Furthermore, IFN-a, but not ARA-C, potentiates the
growth-promoting effect of EGF in KB cells while inducing EGF-
R up-regulation (Caraglia et al, 1995). On this basis, we have
hypothesized that up-regulation of growth factor receptors is a
common event in growth-inhibited tumour cells and could repre-
sent a protective response towards the antiproliferative stimuli
(Tagliaferri et al, 1994). This non-specific response could,
however, result in sensitization to EGF only after treatment of
tumour cells by physiological molecules such as IFN-a.
The key finding of the present study is that 8-Cl-cAMP while
inducing EGF-R up-regulation, this effect being analogous to
other growth inhibiting compounds, also inhibited EGF-stimulated
ERKs activity and antagonized the mitogenic effect of EGF.
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Figure 5 Raf-1 and MEK-1 kinase activity in 8-Cl-cAMP-treated cells. KB
cells growing in exponential phase in the presence or absence of 10 mM
8-Cl-cAMP for 48 h, were stimulated with 10 mM EGF for 5 min. (A) Raf-1 was
immunoprecipitated and analysed for kinase activity by immunocomplex
kinase assay using histone H1 as substrate (Kharbanda et al, 1994). For
Raf-1 protein expression a Western blotting was performed, as described in
Materials and Methods. Lane C1 indicated a control where the
immunocomplex kinase assay was performed on untreated EGF-stimulated
cells in the absence of the substrate. Lane C2 indicated a control assay
performed using non-immune serum to immunoprecipitate untreated
EGF-stimulated cells. (B) MEK-1 and ERK-1 activity was evaluated by gel
retardation experiments using 10% acrylamide gels containing 2% SDS to
improve resolution of closely migrating forms. (C) MEK-1 was
immunoprecipitated and analysed for kinase activity by immunocomplex
kinase assay using as substrate a peptide containing Thr-183 and Tyr-185
within the regulatory sequence common to ERK-1 and ERK-2 (Santa Cruz
Biotechnology Inc, Santa Cruz, CA, USA). For MEK-1 protein expression a
Western blotting was performed, as described in Materials and Methods. C1
and C2 control samples have been assayed as described for Raf-1. Each
experiment shown is representative of at least three experiments that gave
similar results.1140 A Budillon et al
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Furthermore, the 8-Cl-cAMP inhibition of EGF-induced mito-
genic signalling was not dependent on Raf-1 kinase inhibition, and
occurred upstream ERKs but downstream MEK. In fact, we have
found that neither activation nor expression of MEK, which lays
downstream Raf-1 and is the direct activator of ERKs (Denhardt,
1996; Marshal, 1996), were affected by 8-Cl-cAMP treatment.
The mechanism by which 8-Cl-cAMP interfered with ERKs
activation is not known. The results presented in this study suggest
a selective inhibition of 8-Cl-cAMP on ERKs or on a still
unknown upstream activator (Figure 6). While several reports
have demonstrated the possibility of by-passing some steps of the
cascade of events induced by EGF and ultimately activating ERKs
(Faure and Bourne, 1995; Csar et al, 1997), to our knowledge no
other specific activator except MEK has been shown to directly
stimulate ERKs.
Our findings could be interpreted on the basis of the unique
mechanism of action of 8-Cl-cAMP in down-regulating PKA-I
isoenzyme. Since PKA-I expression has been related to cell prolif-
eration and transformation (Miller et al, 1993; Tortora et al, 1993;
Cho-Chung et al, 1995) and 8-Cl-cAMP down-regulates the
expression of RIa subunit of PKA in KB cells (Budillon et al,
unpublished observation), this effect could interfere with EGF-
induced signalling. In this regard, Tortora et al reported that RIa
subunit binds to Gbr2 and allows the interaction of PKA-I with the
activated EGF-R in human breast MCF-10 cells (Tortora et al,
1997a), suggesting a possible interference of PKA-I inhibitors
with the early steps of EGF-R-mediated signalling. In our system
we did not examine if this interaction is present or if it is regulated
by 8-Cl-cAMP. However, we demonstrated that this agent had no
effect on the early steps of EGF-R-mediated signalling. In fact,
our data suggest that, even if the 8-Cl-cAMP effect on ERKs
activation is mediated through RIa down-regulation, this effect
does not occur by depressing the function or the cellular content of
EGF-R in our epidermoid tumour cell system.
Furthermore, it has been hypothesized that 8-Cl-adenosine, the
metabolite derived from 8-Cl-cAMP phosphodiesterase-mediated
degradation, can be responsible for the growth-inhibitory effects
of this agent (Lange-Carter et al, 1993; Langeveld et al, 1997).
However, other investigations have demonstrated that the anti-
tumour activity of 8-Cl-cAMP is not dependent on its metabolite
(Tagliaferri et al, 1988; Rohlff et al, 1993; Cho-Chung et al, 1995;
Noguchi et al, 1998). Moreover, in our experimental conditions,
the effects of 8-Cl-cAMP were not mediated by its metabolite,
since 8-Cl-adenosine did not modify EGF-stimulated or PMA-
stimulated ERK-1 activity.
Several examples of a cross-talk between the transduction path-
ways induced by mitogenic stimuli and the PKA-activated
signalling have been described (Cook and McCormick, 1993; Wu
et al, 1993; Frodin et al, 1994; Hordijk et al, 1994; Vossler et al,
1997). It is well known that cAMP influences negatively the trans-
mission of growth signal through the Ras pathway (Cook and
McCormick, 1993; Wu et al, 1993; Hordijk et al, 1994). In partic-
ular, it has been suggested that PKA induced phosphorylation of
Raf-1 reducing its ability to bind Ras and then blocking the ERKs
signalling (Wu et al, 1993). However, 8-Cl-cAMP is not con-
sidered an activator of PKA, conversely it is rather an antagonist of
PKA-I (Rohlff et al, 1993; Cho-Chung et al, 1995; Scala et al,
1995) which is the major isoenzyme expressed in KB cells
(Budillon et al, unpublished observation). In addition, we have
demonstrated that 8-Cl-cAMP had no effect on Raf-1 kinase
activity in these cells.
Ciardiello et al (1996) have demonstrated a cooperative anti-
tumour effect of 8-Cl-cAMP and anti-EGF-R MAb 528 in vivo on
tumour xenografts. It was proposed that the cooperative effect is
the result of a multiple step inhibition of the EGF-mediated
signalling pathway induced by the two agents. If we consider that
mAb 528 has receptor blocking activity it is conceivable that it
could be potentiated by 8-Cl-cAMP which also hinder the EGF
mitogenic pathway by selective ERKs inhibition. Furthermore, the
up-regulation of EGF-R induced by 8-Cl-cAMP could enhance
mab 528 binding to tumour cells.
In conclusion, our results add new insights into the mechanism
of anti-tumour action of 8-Cl-cAMP demonstrating that this agent
can specifically inhibit the terminal enzymes of EGF/EGF-R
pathway in human cancer cells. Since 8-Cl-cAMP is currently
being investigated as an anticancer agent in phase I studies
(Tortora et al, 1995; Saunders et al, 1997), the identification of the
specific molecular targets of 8-Cl-cAMP may allow the design of
selective approaches in order to enhance the anti-tumour activity
of this compound.
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